1-6 of 6
Authors: Jürgen Rockstroh
Journal Article
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 4, April 2016, Pages 1056–1062, https://doi.org/10.1093/jac/dkv427
Published: 24 December 2015
Journal Article
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study Get access
Journal of Antimicrobial Chemotherapy, Volume 66, Issue 8, August 2011, Pages 1886–1896, https://doi.org/10.1093/jac/dkr171
Published: 30 May 2011
Journal Article
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
Journal of Antimicrobial Chemotherapy, Volume 66, Issue 6, June 2011, Pages 1332–1339, https://doi.org/10.1093/jac/dkr087
Published: 25 March 2011
Journal Article
Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir Get access
Journal of Antimicrobial Chemotherapy, Volume 65, Issue 5, May 2010, Pages 999–1004, https://doi.org/10.1093/jac/dkq054
Published: 04 March 2010
Journal Article
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients Get access
Journal of Antimicrobial Chemotherapy, Volume 61, Issue 4, April 2008, Pages 914–918, https://doi.org/10.1093/jac/dkn029
Published: 14 February 2008
Journal Article
CC-chemokine receptor 5 (CCR5) in hepatitis C—at the crossroads of the antiviral immune response?
Journal of Antimicrobial Chemotherapy, Volume 53, Issue 6, June 2004, Pages 895–898, https://doi.org/10.1093/jac/dkh239
Published: 01 June 2004
